Hofmann, Wolf P.

Publishing since 2003 (Junior)

Has published 30 publications in 8 years

Number of publications published per year by Hofmann, Wolf P.. (Source : PubMed)

Distribution of publications types for Hofmann, Wolf P.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Wedemeyer H, Hofmann WP, Lueth S, Malinski P, Thimme R, Tacke F, Wiegand J. [ALT screening for chronic liver diseases: scrutinizing the evidence]  Z Gastroenterol  2010;48;1  
•  Lange CM, Bojunga J, Hofmann WP, Wunder K, Mihm U, Zeuzem S, Sarrazin C. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.  Hepatology  2009;50;6  
•  Akoglu B, Kriener S, Martens S, Herrmann E, Hofmann WP, Milovic V, Zeuzem S, Faust D. Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients.  Clin. Exp. Med.  2009;9;4  
•  Lange CM, Hofmann WP, Kriener S, Jacobi V, Welsch C, Just-Nuebling G, Zeuzem S. Primary actinomycosis of the liver mimicking malignancy.  Z Gastroenterol  2009;47;10  
•  Mihm U, Hofmann WP, Welsch C, Polta A, Lengauer T, Zeuzem S, Sarrazin C, Herrmann E. Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome.  J. Viral Hepat.  2009  
•  Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.  Vaccine  2009;27;37  
•  Hofmann WP, Zeuzem S. Hepatitis C: new therapeutic strategies needed for advanced disease.  Nat Rev Gastroenterol Hepatol  2009;6;6  
•  Hofmann WP, Zeuzem S. Advanced chronic hepatitis C: how to handle if you cannot halt?  Hepatology  2009;49;4  
•  Mihm U, Ackermann O, Welsch C, Herrmann E, Hofmann WP, Grigorian N, Welker MW, Lengauer T, Zeuzem S, Sarrazin C. Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C.  J. Hepatol.  2009;50;1  
•  Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms.  Liver Int.  2008;28;10  

[ See timeline ] [ See all publications ]